{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:59:00Z","timestamp":1794315540393,"version":"4.9.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There is evidence that a history of benign prostatic hyperplasia increases the incidence of bladder cancer, and treatment with 5-alpha reductase inhibitor or androgen deprivation therapy reduces recurrence of non-muscle invasive bladder cancer. We aimed to evaluate whether prostate volume affects its prognosis. We reviewed medical records of men who underwent transurethral resection of bladder tumor due to non-muscle invasive bladder cancer from January 2012 to December 2017. Patients were divided into two groups based on prostate volume measured by computed tomography (group 1: 264 patients with\u2009\u2264\u200930\u00a0mL, group 2: 124 patients with\u2009&gt;\u200930\u00a0mL). Propensity score matching analysis was used for adjust selection bias, and then assessed recurrence-free survival and progression-free survival. With a median follow up duration of 52\u00a0months, group 1 showed higher 5-year recurrence-free and progression-free survival (69.3% vs 47.0%, p\u2009=\u20090.001; 96.7% vs 87.7%, p\u2009=\u20090.002). Further, cox-regression analysis showed that tumor size (HR\u2009=\u20091.292 p\u2009&lt;\u20090.001), multifocal tumor (HR\u2009=\u20091.993, p\u2009&lt;\u20090.001), adjuvant intravesical therapy (chemotherapy: HR\u2009=\u20090.580, p\u2009=\u20090.037 and bacillus Calmette\u2013Gu\u00e9rin: HR\u2009=\u20090.542, p\u2009=\u20090.004) and prostate volume (HR\u2009=\u20092.326, p\u2009&lt;\u20090.001) were significant predictors of recurrence-free survival. Prostate volume (HR\u2009=\u20092.886, p\u2009=\u20090.014) was also associated with PFS with age (HR\u2009=\u20091.043, p\u2009=\u20090.044) and tumor grade (HR\u2009=\u20093.822, p\u2009=\u20090.013). We conclude higher prostate volume is associated with worse recurrence and progression-free survival in non-muscle invasive bladder cancer.<\/jats:p>","DOI":"10.1038\/s41598-021-98045-1","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T10:03:10Z","timestamp":1632304990000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prognostic value of prostate volume in non-muscle invasive bladder cancer"],"prefix":"10.1038","volume":"11","author":[{"given":"Won Sik","family":"Ham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Sik","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Deuk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongchan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,22]]},"reference":[{"key":"98045_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"98045_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger, M. et al. Epidemiology and risk factors of urothelial bladder cancer. Eur. Urol. 63, 234\u2013241. https:\/\/doi.org\/10.1016\/j.eururo.2012.07.033 (2013).","journal-title":"Eur. Urol."},{"key":"98045_CR3","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49, 466\u2013465. https:\/\/doi.org\/10.1016\/j.eururo.2005.12.031 (2006) (discussion 475\u2013467).","journal-title":"Eur. Urol."},{"key":"98045_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","volume":"69","author":"S Cambier","year":"2016","unstructured":"Cambier, S. et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance Bacillus Calmette\u2013Gu\u00e9rin. Eur. Urol. 69, 60\u201369. https:\/\/doi.org\/10.1016\/j.eururo.2015.06.045 (2016).","journal-title":"Eur. Urol."},{"key":"98045_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/ju.0000000000001029","volume":"204","author":"MF Becerra","year":"2020","unstructured":"Becerra, M. F. et al. Health related quality of life of patients with bladder cancer in the RAZOR trial: A multi-institutional randomized trial comparing robot versus open radical cystectomy. J. Urol. 204, 450\u2013459. https:\/\/doi.org\/10.1097\/ju.0000000000001029 (2020).","journal-title":"J. Urol."},{"key":"98045_CR6","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez, J. et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette\u2013Guerin: The CUETO scoring model. J. Urol. 182, 2195\u20132203. https:\/\/doi.org\/10.1016\/j.juro.2009.07.016 (2009).","journal-title":"J. Urol."},{"key":"98045_CR7","doi-asserted-by":"publisher","first-page":"17022","DOI":"10.1038\/nrdp.2017.22","volume":"3","author":"O Sanli","year":"2017","unstructured":"Sanli, O. et al. Bladder cancer. Nat. Rev. Dis. Primers 3, 17022. https:\/\/doi.org\/10.1038\/nrdp.2017.22 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"98045_CR8","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","volume":"69","author":"TJ Arends","year":"2016","unstructured":"Arends, T. J. et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette\u2013Gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur. Urol. 69, 1046\u20131052. https:\/\/doi.org\/10.1016\/j.eururo.2016.01.006 (2016).","journal-title":"Eur. Urol."},{"key":"98045_CR9","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/0277-5379(82)90103-1","volume":"18","author":"S Mommsen","year":"1982","unstructured":"Mommsen, S., Aagaard, J. & Sell, A. An epidemiological case\u2013control study of bladder cancer in males from a predominantly rural district. Eur. J. Cancer Clin. Oncol. 18, 1205\u20131210. https:\/\/doi.org\/10.1016\/0277-5379(82)90103-1 (1982).","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"98045_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000003493","volume":"95","author":"X Dai","year":"2016","unstructured":"Dai, X., Fang, X., Ma, Y. & Xianyu, J. Benign prostatic hyperplasia and the risk of prostate cancer and bladder cancer: A meta-analysis of observational studies. Medicine (Baltimore) 95, e3493. https:\/\/doi.org\/10.1097\/md.0000000000003493 (2016).","journal-title":"Medicine (Baltimore)"},{"key":"98045_CR11","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.juro.2016.08.006","volume":"197","author":"M Shiota","year":"2017","unstructured":"Shiota, M. et al. Suppressed recurrent bladder cancer after androgen suppression with androgen deprivation therapy or 5\u03b1-reductase inhibitor. J. Urol. 197, 308\u2013313. https:\/\/doi.org\/10.1016\/j.juro.2016.08.006 (2017).","journal-title":"J. Urol."},{"key":"98045_CR12","doi-asserted-by":"publisher","first-page":"12665","DOI":"10.18632\/oncotarget.2851","volume":"5","author":"K Izumi","year":"2014","unstructured":"Izumi, K. et al. Androgen deprivation therapy prevents bladder cancer recurrence. Oncotarget 5, 12665\u201312674. https:\/\/doi.org\/10.18632\/oncotarget.2851 (2014).","journal-title":"Oncotarget"},{"key":"98045_CR13","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMo\u010356","volume":"349","author":"JD McConnell","year":"2003","unstructured":"McConnell, J. D. et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. 349, 2387\u20132398. https:\/\/doi.org\/10.1056\/NEJMo\u010356 (2003).","journal-title":"N. Engl. J. Med."},{"key":"98045_CR14","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1111\/j.1464-410X.2012.11107.x","volume":"110","author":"K Axcrona","year":"2012","unstructured":"Axcrona, K. et al. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: Degarelix vs goserelin plus bicalutamide. BJU Int. 110, 1721\u20131728. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11107.x (2012).","journal-title":"BJU Int."},{"key":"98045_CR15","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1016\/j.ajpath.2013.02.028","volume":"182","author":"K Izumi","year":"2013","unstructured":"Izumi, K., Mizokami, A., Lin, W. J., Lai, K. P. & Chang, C. Androgen receptor roles in the development of benign prostate hyperplasia. Am. J. Pathol. 182, 1942\u20131949. https:\/\/doi.org\/10.1016\/j.ajpath.2013.02.028 (2013).","journal-title":"Am. J. Pathol."},{"key":"98045_CR16","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1590\/s1677-5538.Ibju.2018.0068","volume":"45","author":"A Lunney","year":"2019","unstructured":"Lunney, A., Haynes, A. & Sharma, P. Moderate or severe LUTS is associated with increased recurrence of non-muscle-invasive urothelial carcinoma of the bladder. Int. Braz. J. Urol. 45, 306\u2013314. https:\/\/doi.org\/10.1590\/s1677-5538.Ibju.2018.0068 (2019).","journal-title":"Int. Braz. J. Urol."},{"key":"98045_CR17","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.eururo.2014.12.038","volume":"67","author":"C Gratzke","year":"2015","unstructured":"Gratzke, C. et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur. Urol. 67, 1099\u20131109. https:\/\/doi.org\/10.1016\/j.eururo.2014.12.038 (2015).","journal-title":"Eur. Urol."},{"key":"98045_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9020020","volume":"9","author":"P Li","year":"2017","unstructured":"Li, P., Chen, J. & Miyamoto, H. Androgen receptor signaling in bladder cancer. Cancers (Basel) 9, 20. https:\/\/doi.org\/10.3390\/cancers9020020 (2017).","journal-title":"Cancers (Basel)"},{"key":"98045_CR19","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3892\/mco.2017.1389","volume":"7","author":"J Chen","year":"2017","unstructured":"Chen, J. et al. Expression and clinical significance of androgen receptor in bladder cancer: A meta-analysis. Mol. Clin. Oncol. 7, 919\u2013927. https:\/\/doi.org\/10.3892\/mco.2017.1389 (2017).","journal-title":"Mol. Clin. Oncol."},{"key":"98045_CR20","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1186\/s12885-020-07373-4","volume":"20","author":"CS Wang","year":"2020","unstructured":"Wang, C. S., Li, C. C., Juan, Y. S., Wu, W. J. & Lee, H. Y. 5\u03b1-reductase inhibitors impact prognosis of urothelial carcinoma. BMC Cancer 20, 872. https:\/\/doi.org\/10.1186\/s12885-020-07373-4 (2020).","journal-title":"BMC Cancer"},{"key":"98045_CR21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ajpath.2014.10.012","volume":"185","author":"S Wen","year":"2015","unstructured":"Wen, S. et al. Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer. Am. J. Pathol. 185, 293\u2013301. https:\/\/doi.org\/10.1016\/j.ajpath.2014.10.012 (2015).","journal-title":"Am. J. Pathol."},{"key":"98045_CR22","first-page":"860","volume":"39","author":"D Milonas","year":"2003","unstructured":"Milonas, D., Trumbeckas, D. & Juska, P. The importance of prostatic measuring by transrectal ultrasound in surgical management of patients with clinically benign prostatic hyperplasia. Medicina (Kaunas) 39, 860\u2013866 (2003).","journal-title":"Medicina (Kaunas)"},{"key":"98045_CR23","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1046\/j.1464-410x.1999.00214.x","volume":"84","author":"AR Zlotta","year":"1999","unstructured":"Zlotta, A. R. et al. The importance of measuring the prostatic transition zone: An anatomical and radiological study. BJU Int. 84, 661\u2013666. https:\/\/doi.org\/10.1046\/j.1464-410x.1999.00214.x (1999).","journal-title":"BJU Int."},{"key":"98045_CR24","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7029450","volume":"2019","author":"SH Kim","year":"2019","unstructured":"Kim, S. H. et al. Correlation analyses of computed tomography and magnetic resonance imaging for calculation of prostate volume in colorectal cancer patients with voiding problems who cannot have transrectal ultrasonography. Biomed. Res. Int. 2019, 7029450. https:\/\/doi.org\/10.1155\/2019\/7029450 (2019).","journal-title":"Biomed. Res. Int."},{"key":"98045_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/bju.12917","volume":"116","author":"GM Busetto","year":"2015","unstructured":"Busetto, G. M. et al. Short-term pretreatment with a dual 5\u03b1-reductase inhibitor before bipolar transurethral resection of the prostate (B-TURP): Evaluation of prostate vascularity and decreased surgical blood loss in large prostates. BJU Int. 116, 117\u2013123. https:\/\/doi.org\/10.1111\/bju.12917 (2015).","journal-title":"BJU Int."},{"key":"98045_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203479","volume":"13","author":"JH Kim","year":"2018","unstructured":"Kim, J. H. et al. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis. PLoS\u00a0One 13, e0203479. https:\/\/doi.org\/10.1371\/journal.pone.0203479 (2018).","journal-title":"PLoS\u00a0One"},{"key":"98045_CR27","first-page":"4371","volume":"51","author":"FF Kadlubar","year":"1991","unstructured":"Kadlubar, F. F. et al. Frequency of urination and its effects on metabolism, pharmacokinetics, blood hemoglobin adduct formation, and liver and urinary bladder DNA adduct levels in beagle dogs given the carcinogen 4-aminobiphenyl. Cancer Res. 51, 4371\u20134377 (1991).","journal-title":"Cancer Res."},{"key":"98045_CR28","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1136\/bmj.318.7195.1372","volume":"318","author":"F Charatan","year":"1999","unstructured":"Charatan, F. Fluid intake affects the risk of bladder cancer in men. BMJ 318, 1372. https:\/\/doi.org\/10.1136\/bmj.318.7195.1372 (1999).","journal-title":"BMJ"},{"key":"98045_CR29","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.urolonc.2020.02.016","volume":"38","author":"M Ferro","year":"2020","unstructured":"Ferro, M. et al. Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette\u2013Gu\u00e9rin after transurethral resection of the bladder tumor. Urol. Oncol. 38, 459\u2013464. https:\/\/doi.org\/10.1016\/j.urolonc.2020.02.016 (2020).","journal-title":"Urol. Oncol."},{"key":"98045_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00345-019-02754-2","volume":"38","author":"M Ferro","year":"2020","unstructured":"Ferro, M. et al. Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette\u2013Gu\u00e9rin after transurethral resection of the bladder tumor. World J. Urol. 38, 143\u2013150. https:\/\/doi.org\/10.1007\/s00345-019-02754-2 (2020).","journal-title":"World J. Urol."},{"key":"98045_CR31","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00432-017-2449-8","volume":"143","author":"C Nicolazzo","year":"2017","unstructured":"Nicolazzo, C. et al. The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC). J. Cancer Res. Clin. Oncol. 143, 1971\u20131976. https:\/\/doi.org\/10.1007\/s00432-017-2449-8 (2017).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"98045_CR32","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1634\/theoncologist.2018-0784","volume":"24","author":"C Nicolazzo","year":"2019","unstructured":"Nicolazzo, C. et al. Circulating tumor cells identify patients with super-high-risk non-muscle-invasive bladder cancer: Updated outcome analysis of a prospective single-center trial. Oncologist 24, 612\u2013616. https:\/\/doi.org\/10.1634\/theoncologist.2018-0784 (2019).","journal-title":"Oncologist"},{"key":"98045_CR33","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.juro.2008.11.099","volume":"181","author":"WS Ham","year":"2009","unstructured":"Ham, W. S., Kim, W. T., Jeon, H. J., Lee, D. H. & Choi, Y. D. Long-term outcome of simultaneous transurethral resection of bladder tumor and prostate in patients with nonmuscle invasive bladder tumor and bladder outlet obstruction. J. Urol. 181, 1594\u20131599. https:\/\/doi.org\/10.1016\/j.juro.2008.11.099 (2009) (discussion 1599).","journal-title":"J. Urol."},{"key":"98045_CR34","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s00345-018-2317-4","volume":"36","author":"M Dellabella","year":"2018","unstructured":"Dellabella, M., Branchi, A., Gasparri, L., Claudini, R. & Castellani, D. Oncological safety and quality of life in men undergoing simultaneous transurethral resection of bladder tumor and prostate: Results from a randomized controlled trial. World J. Urol. 36, 1629\u20131634. https:\/\/doi.org\/10.1007\/s00345-018-2317-4 (2018).","journal-title":"World J. Urol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98045-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98045-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98045-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T15:56:53Z","timestamp":1670083013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98045-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,22]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["98045"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-98045-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,22]]},"assertion":[{"value":"23 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18784"}}